[go: up one dir, main page]

SK279684B6 - Tableta a spôsob jej výroby - Google Patents

Tableta a spôsob jej výroby Download PDF

Info

Publication number
SK279684B6
SK279684B6 SK1555-95A SK155595A SK279684B6 SK 279684 B6 SK279684 B6 SK 279684B6 SK 155595 A SK155595 A SK 155595A SK 279684 B6 SK279684 B6 SK 279684B6
Authority
SK
Slovakia
Prior art keywords
coating
pseudoephedrine hydrochloride
tablet
core
hydrophilic polymer
Prior art date
Application number
SK1555-95A
Other languages
English (en)
Slovak (sk)
Other versions
SK155595A3 (en
Inventor
Paul M. V. Gilis
Eugene M. J. Jans
Guido J. M. Gijs
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of SK155595A3 publication Critical patent/SK155595A3/sk
Publication of SK279684B6 publication Critical patent/SK279684B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SK1555-95A 1993-06-14 1994-06-07 Tableta a spôsob jej výroby SK279684B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP93201697 1993-06-14
PCT/EP1994/001878 WO1994028880A1 (en) 1993-06-14 1994-06-07 Extended release, film-coated tablet of astemizole and pseudoephedrine

Publications (2)

Publication Number Publication Date
SK155595A3 SK155595A3 (en) 1997-02-05
SK279684B6 true SK279684B6 (sk) 1999-02-11

Family

ID=8213895

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1555-95A SK279684B6 (sk) 1993-06-14 1994-06-07 Tableta a spôsob jej výroby

Country Status (21)

Country Link
US (1) US5681582A (sl)
EP (1) EP0707475B1 (sl)
JP (1) JPH08511257A (sl)
KR (1) KR100337985B1 (sl)
CN (1) CN1071570C (sl)
AT (1) ATE158178T1 (sl)
AU (1) AU675557B2 (sl)
CA (1) CA2163121A1 (sl)
CZ (1) CZ284822B6 (sl)
DE (1) DE69405752T2 (sl)
DK (1) DK0707475T3 (sl)
ES (1) ES2107235T3 (sl)
FI (1) FI955979A (sl)
GR (1) GR3025550T3 (sl)
HU (1) HU219462B (sl)
NO (1) NO311918B1 (sl)
NZ (1) NZ268003A (sl)
SI (1) SI9420040A (sl)
SK (1) SK279684B6 (sl)
WO (1) WO1994028880A1 (sl)
ZA (1) ZA944162B (sl)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110196039A9 (en) * 1994-10-05 2011-08-11 Kaesemeyer Wayne H Controlled release arginine formulations
US5558879A (en) * 1995-04-28 1996-09-24 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ
EP0811374A1 (en) 1996-05-29 1997-12-10 Pfizer Inc. Combination dosage form comprising cetirizine and pseudoephedrine
US5895663A (en) * 1997-07-31 1999-04-20 L. Perrigo Company Pseudoephedrine hydrochloride extended-release tablets
FR2771291B1 (fr) * 1997-11-21 2000-02-25 Ethypharm Lab Prod Ethiques Spheroides, procede de preparation et compositions pharmaceutiques
DE19821625C1 (de) * 1998-05-15 2000-01-05 Merck Patent Gmbh Pharmazeutische Zubereitung
JP2002523358A (ja) * 1998-08-25 2002-07-30 プラット，クリス ナプロキセンおよびプソイドエフェドリンを含む徐法性錠剤
PL349501A1 (en) * 1998-12-24 2002-07-29 Janssen Pharmaceutica Nv Controlled release galantamine composition
US6432448B1 (en) 1999-02-08 2002-08-13 Fmc Corporation Edible coating composition
US6723342B1 (en) 1999-02-08 2004-04-20 Fmc Corporation Edible coating composition
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US6251432B1 (en) * 1999-07-01 2001-06-26 Abbott Laboratories Sustained release dosage form unit having latex coating and method of making the same
SE9903879D0 (sv) * 1999-10-28 1999-10-28 Ethical Pharmaceuticals Sweden Multipor food protection
US6500462B1 (en) 1999-10-29 2002-12-31 Fmc Corporation Edible MCC/PGA coating composition
IN192159B (sl) * 2000-05-15 2004-02-28 Ranbaxy Lab Ltd
US20020094345A1 (en) * 2000-10-06 2002-07-18 Sara Abelaira Pharmaceutical compositions containing epinastine and pseudoephedrine
US6699315B2 (en) 2000-11-28 2004-03-02 Fmc Corporation Edible PGA coating composition
US7125563B2 (en) 2002-04-12 2006-10-24 Dava Pharmaceuticals, Inc. Sustained release pharmaceutical preparations and methods for producing the same
KR100602235B1 (ko) * 2002-07-09 2006-07-19 한국맥널티 주식회사 방출제어형 약제학적 조성물의 제조방법
US6663892B1 (en) 2002-08-19 2003-12-16 L. Perrigo Company Multiple portion tablet
US7115283B2 (en) * 2003-05-06 2006-10-03 Access Business Group International Llc Preparations for sustained release of nutraceuticals and methods of controllably releasing nutraceuticals
US7713550B2 (en) * 2004-06-15 2010-05-11 Andrx Corporation Controlled release sodium valproate formulation
JP5688877B2 (ja) 2005-11-11 2015-03-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌疾患の治療用キナゾリン誘導体
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) * 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
RU2009133447A (ru) * 2007-02-09 2011-03-20 Пониард Фармасьютикалз, Инк. (Us) Дозированная форма пикоплатина
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
SG187455A1 (en) * 2008-01-11 2013-02-28 Teva Pharma Rasagiline formulations, their preparation and use
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
US8778398B2 (en) 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
US20100260842A1 (en) * 2009-04-06 2010-10-14 Rashmi Nair Pseudoephedrine pharmaceutical formulations
HUE044629T2 (hu) 2009-07-06 2019-11-28 Boehringer Ingelheim Int Eljárás BIBW2992, annak sói, valamint e hatóanyagot tartalmazó szilárd gyógyászati készítmények szárítására
KR101193495B1 (ko) * 2010-02-01 2012-10-23 한미사이언스 주식회사 슈도에페드린 및 레보세티리진을 포함하는 경구용 복합 조성물
JP5968300B2 (ja) 2010-03-24 2016-08-10 ジャズ、ファーマシューティカルズ、インコーポレイテッドＪａｚｚ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 高用量、水溶性及び吸湿性薬剤基質用の制御放出性剤形
US20120070465A1 (en) 2010-03-29 2012-03-22 Astellas Pharma Inc. Pharmaceutical composition for modified release
CN102247368B (zh) * 2011-05-19 2013-05-29 安徽永生堂药业有限责任公司 一种复方阿伐斯汀缓释片及其制备方法
CN107252420A (zh) * 2011-05-20 2017-10-17 阿斯利康(英国)有限公司 罗苏伐他汀钙的药物组合物
WO2013023250A1 (en) 2011-08-16 2013-02-21 Baker Idi Heart & Diabetes Institute Holdings Limited Controlled-release formulation
CN107530337B (zh) 2014-12-22 2021-07-09 贝克心脏与糖尿病研究所 治疗方法
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
CA3115122A1 (en) 2018-11-19 2020-05-28 Jazz Pharmaceuticals Ireland Limited Alcohol-resistant drug formulations
CN113473980A (zh) 2019-03-01 2021-10-01 弗拉梅尔爱尔兰有限公司 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
IL70071A (en) * 1982-11-01 1987-12-31 Merrell Dow Pharma Multilayered sustained release pharmaceutical tablets having non-uniform distribution of active ingredient
US4829064A (en) * 1987-06-08 1989-05-09 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
US4975426A (en) * 1987-06-08 1990-12-04 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
US4996061A (en) * 1987-10-07 1991-02-26 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol-decongestant combination
CN1053570C (zh) * 1987-10-07 2000-06-21 默尔多药物公司 哌啶子基链烷醇的药用组合物-减充血剂复方的制备方法
US4999226A (en) * 1988-06-01 1991-03-12 Merrell Dow Pharmaceuticals Inc. Pharmaceutical compositions for piperidinoalkanol-ibuprofen combination
US4990535A (en) * 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
US5595997A (en) * 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
US6114346A (en) * 1999-10-22 2000-09-05 Schering Corporation Treating sleep disorders using desloratadine

Also Published As

Publication number Publication date
HU9501922D0 (en) 1995-09-28
EP0707475B1 (en) 1997-09-17
ES2107235T3 (es) 1997-11-16
DE69405752T2 (de) 1998-02-05
DE69405752D1 (de) 1997-10-23
CN1071570C (zh) 2001-09-26
US5681582A (en) 1997-10-28
SI9420040A (en) 1996-08-31
FI955979A0 (fi) 1995-12-13
JPH08511257A (ja) 1996-11-26
AU675557B2 (en) 1997-02-06
CZ324595A3 (en) 1996-03-13
FI955979A (fi) 1995-12-13
CN1125396A (zh) 1996-06-26
KR100337985B1 (ko) 2002-11-23
AU7071494A (en) 1995-01-03
HU219462B (hu) 2001-04-28
WO1994028880A1 (en) 1994-12-22
NO955027D0 (no) 1995-12-12
CA2163121A1 (en) 1994-12-22
ATE158178T1 (de) 1997-10-15
NO955027L (no) 1995-12-12
GR3025550T3 (en) 1998-03-31
ZA944162B (en) 1995-12-13
EP0707475A1 (en) 1996-04-24
CZ284822B6 (cs) 1999-03-17
NO311918B1 (no) 2002-02-18
NZ268003A (en) 1996-11-26
DK0707475T3 (da) 1997-12-29
SK155595A3 (en) 1997-02-05
HUT73768A (en) 1996-09-30

Similar Documents

Publication Publication Date Title
SK279684B6 (sk) Tableta a spôsob jej výroby
US5472712A (en) Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5188840A (en) Slow-release pharmaceutical agent
US6893661B1 (en) Controlled release formulations using intelligent polymers
FI94094C (fi) Kantajakoostumus kestovaikutteiselle lääkeainevalmisteelle
US20090124702A1 (en) Pharmaceutical Compositions of Metformin
SK135496A3 (en) Tablet preparation, producing method and its use
NZ551591A (en) Coated tablet formulation and method
US20110195120A2 (en) Sustained Release Pharmaceutical Composition Containing Metformin Hydrochloride
MXPA05004410A (es) Composiciones de liberacion controlada.
US20030099710A1 (en) Granule modulating hydrogel system
US5322698A (en) Process for the preparation of a tablet or dragee composition containing a heat-, light- and moisture-sensitive active ingredient having monoclinic crystal structure
US20070196500A1 (en) Composition for oral administration of tamsulosin hydrochloride and controlled release granule formulation comprising same
CZ287149B6 (en) Pharmaceutical preparation containing gemfibrozil
US20050042279A1 (en) Pharmaceutical formulation comprising more than 15% tamoxifen
CA3048968A1 (en) Oral pharmaceutical composition of lurasidone and preparation thereof
CZ146494A3 (en) Ipsapirone healing preparation
US20040228918A1 (en) Granule modulating hydrogel system
MXPA06009141A (en) Composition for oral administration of tamsulosin hydrochloride and controlled release granule formulation comprising same